Perez Rodriguez
Alberto Perez Rodriguez, Zalla (bizkaia) ES
Patent application number | Description | Published |
---|---|---|
20110186173 | SAFETY CABINET FOR FILLING SELF-CONTAINED BREATHING APPARATUS BOTTLES - Safety cabinet for filling self-contained breathing apparatus bottles comprising a housing body with high-strength walls, openable on its front and top sides and forming a work surface fitted with a plurality of tapered rubber rollers, linked at their narrow ends and arranged to form a bed of supporting rollers for the bottles to be filled, arranged horizontally and to which the respective filling taps are attached. The housing body is closed using a vertical front door and a horizontal top door. | 08-04-2011 |
Alejandro Pérez Rodríguez, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20120104765 | DEVICE FOR GENERATING ELECTRIC POWER FROM SMALL MOVEMENTS - This invention describes a device for the generation of electric energy from small movements which comprises: a magnet with the shape of a solid of revolution which comprises at least a couple of poles (N, S) placed around an axis of revolution; a tube whose transversal section is complementary to the shape of the magnet, and which comprises a winding rolled transversally around it, with the magnet placed in the interior of the tube so that an inclination of the tube causes the magnet to roll, traveling along the interior of the tube and inducing tension on the winding. | 05-03-2012 |
Arturo Perez Rodriguez, Madrid ES
Patent application number | Description | Published |
---|---|---|
20150084472 | Electrical Power Motor-Generator Excited by Magnetic Transference - The invention relates to an electrical power motor-generator excited by magnetic transference, and which further comprises a stator ( | 03-26-2015 |
Diana Perez Rodriguez, Gustavo A. Madero MX
Patent application number | Description | Published |
---|---|---|
20160088855 | METHOD FOR THE MANUFACTURE OF A CREAM CHEESE - The present disclosure relates to a method for the manufacture of a cream cheese, the method comprising: | 03-31-2016 |
Doris S. Perez Rodriguez, Arlington Heights, IL US
Patent application number | Description | Published |
---|---|---|
20130179207 | Method and Apparatus for High Performance Design of a Project - Method, apparatus, and program for high performance design of a project. A goal of the project to meet at least one sustainability criterion is first received. A design strategy is then associated with the goal of the project in accordance with the at least one sustainability criterion. The design strategy is created based on a common design approach. A design task is further associated with the design strategy at each phase of the project in accordance with the at least one sustainability criterion. The design task is created to implement the design strategy. A goal metric for the at least one sustainability criterion at each phase of the project is then dynamically calculated based on information of the project from a database. Eventually, progress of meeting the at least one sustainability criterion is dynamically updated based on the calculated goal metric. | 07-11-2013 |
Gabriel O. Perez Rodriguez, Miramar, FL US
Patent application number | Description | Published |
---|---|---|
20140222451 | PROGRAM OPTIMIZATION SYSTEM - Program optimization systems are provided herein. The program optimization system can include a plurality of data sources that can be mined for information relating to one or several patients. The format and content of the information from the data sources can be evaluated and can be conformed to formats and content types used by the program optimization system. The information retrieved from the data sources can be evaluated for one or several trigger events. If a trigger event is identified in the retrieved data, a treatment protocol can be selected. | 08-07-2014 |
Milagros Perez Rodriguez, Badajoz ES
Patent application number | Description | Published |
---|---|---|
20110053888 | Mixture Of Carboyhydrates And Its Use In The Preparation Of A Product Intended For Oral Or Enteral Nutrition - The present invention is related to a new mixture of carbohydrates and its usage for the preparation of a food product intended for oral or enteral nutrition, particularly for the nutrition of the diabetic patient and in particular for the nutrition of the diabetes type II patient and their associated comorbidity. The carbohydrate mixture of the present invention is formed by type IV or RS IV (modified maltodextrins) resistant starch, maltodextrin of low dextrose equivalent DE=5-8, preferably DE equal to 6, insulin and cellulose and is exempt from fructose. | 03-03-2011 |
20130136800 | Enteral Or Oral Food Product Intended, In Particular, For nutrition And For The Prevention And Improvement Of Neurological Alterations, Neurodegenerative Alterations or Cognitive Disorders - The present invention relates to a complete food product for specific nutritional use, especially intended for enteral or oral nutrition of patients who suffer neurological or neurodegenerative alterations, and for the prevention of cognitive or behaviour disorders, especially in the case of elderly persons, such food product comprising a functional ingredient especially conceived for the nourishment of patients suffering from, or prone to neurological or neurodegenerative alterations, cognitive deterioration or behaviour disorders, as well as a mixture of carbohydrates, a mixture of proteins, a mixture of lipids and dietary fibre, inulin, vitamins and minerals. | 05-30-2013 |
20130172286 | Functional Food Supplement Intended, In Particular, For Nutrition And For Prevention And Improvement of Neurological Alterations, Neurodegenerative Alterations Or Cognitive Disorders - This invention relates to a functional food supplement, specifically intended to supplement the enteral or oral nutrition of patients with neurological or neurodegenerative alterations, and for the prevention of cognitive or behaviour disorders, especially in the case of elderly persons, where the functional ingredient especially conceived for the nourishment of patients suffering from, or prone to neurological or neurodegenerative alterations, cognitive deterioration or behaviour disorders comprises a mixture of UMP (uridine monophosphate or uridine) and/or IMP (inosine monophosphate or inosine), vitamins of the B group (B1, B6, B9 and B7), phospholipids and gangliosides and sialic acid, as well as a large amount of DHA. | 07-04-2013 |
Pablo Perez Rodriguez, Dublin IE
Patent application number | Description | Published |
---|---|---|
20130275685 | INTELLIGENT DATA PRE-CACHING IN A RELATIONAL DATABASE MANAGEMENT SYSTEM - Methods and apparatus, including computer program products, implementing and using techniques for pre-caching information in a database management system. Usage patterns of the database are analyzed to identify regularly recurring requests for information stored in the database. Based on the analyzed usage patterns, a pre-caching strategy is determined. The pre-caching strategy identifies information in the database that is likely to satisfy an anticipated future request. Prior to a time at which the future request is anticipated to be received, a cache in the database is populated with information that satisfies the anticipated future request in accordance with the determined pre-caching strategy. The information that populates the cache is retrieved from a storage medium that is slower to access than the cache. | 10-17-2013 |
Rolando Perez Rodriguez, Ciudad Habana CU
Patent application number | Description | Published |
---|---|---|
20100197011 | METHOD OF OBTAINING CELL LINES IN A PROTEIN-FREE MEDIUM AND CELL LINES THUS OBTAINED - A method of recovering mammalian cell clones adapted to serum and protein-free media is disclosed. The procedure includes a two-stage adaptation process to grow in that condition. A critical protein concentration interval is disclosed in which cells must grow in order to gain the capacity to survive in serum and protein-free condition, once the cells have grown at the critical interval concentrations, subsequent decreases of the concentration will affect neither viability nor cellular doubling time. The critical protein concentration interval is cell line specific. Furthermore, mammalian cells clones are disclosed, which are stable in serum- and protein-free media for at least 40 generations; additionally, clones disclosed express a recombinant product. The cell clones disclosed produce the humanized anti-EGF-R antibody hR3, the humanized anti-CD6 antibody T1hT, the chimeric anti CD3 antibody T3Q, or fragments thereof. | 08-05-2010 |
Rolando Perez Rodriguez, C. Habana CU
Patent application number | Description | Published |
---|---|---|
20100047242 | PHARMACEUTICAL COMPOSITIONS CAPABLE OF INDUCING APOPTOSIS IN TUMOUR CELLS, USEFUL FOR DIAGNOSIS AND TREATMENT OF B-CHRONIC LYMPHOCYTIC LEUKAEMIA - The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions comprising a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions comprising a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Lymphoproliferative Syndromes and particularly the B-Cell Chronic Lymphocytic Leukemia. The essence of the invention consist in the application of a humanized Monoclonal Antibody that recognizes the CD6 antigen, the generation of pharmaceutical compositions comprising that antibody being able to induce apoptosis of malignant cells from B-Cell Chronic Lymphocytic Leukemia patients, reaching a clinical and a histological antitumor efficacy. The field of application of the present invention extends to the Oncology. | 02-25-2010 |
20100092423 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS - The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis. | 04-15-2010 |
20160024220 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS - The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis. | 01-28-2016 |
Samuel Pérez Rodríguez, Provincia Habana CU
Patent application number | Description | Published |
---|---|---|
20120315245 | IMMUNOMODULATOR POLYPEPTIDES DERIVED FROM IL-2 AND THEIR USE THEREOF IN THE THERAPEUTIC OF CANCER AND CHRONIC INFECTIONS - The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases. | 12-13-2012 |
Samuel Pérez Rodríguez, Provincia Habana CU
Patent application number | Description | Published |
---|---|---|
20120315245 | IMMUNOMODULATOR POLYPEPTIDES DERIVED FROM IL-2 AND THEIR USE THEREOF IN THE THERAPEUTIC OF CANCER AND CHRONIC INFECTIONS - The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases. | 12-13-2012 |
Saumel Pérez Rodríguez, Bauta CU
Patent application number | Description | Published |
---|---|---|
20140314709 | IL-2 DERIVATIVES POLYPEPTIDES WITH AGONIST ACTIVITY FOR THERAPY OF CANCER AND CHRONIC INFECTIONS - The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptidess and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases. | 10-23-2014 |
20150284441 | TGFBeta-derived polypeptides and uses thereof - The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGFβ molecule whose primary sequence has a high homology with the sequence of human TGFβ. These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (TβRII and TβRIII). They have the property of antagonizing the signaling of all natural variants of TGFβ ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases. | 10-08-2015 |